(R)(+)-N-Propargyl-1-aminoindan (rasagiline) and derivatives: Highly selective and potent inhibitors of monoamine oxidase B

Journal of Neural Transmission, Supplement

Volumn , Issue 52, 1998, Pages 301-305

  Sterling, J ^a   Veinberg, A ^a   Lerner, D ^a   Goldenberg, W ^a   Levy, R ^a   Youdim, M ^b   Finberg, J ^b  

^a TEVA PHARMACEUTICALS   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; MONOAMINE OXIDASE B INHIBITOR; N (2 PROPYNYL) 1 INDANAMINE; RASAGILINE; UNCLASSIFIED DRUG; AMINE OXIDASE (FLAVIN CONTAINING); INDAN DERIVATIVE; ISOENZYME; MONOAMINE OXIDASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN; DRUG SELECTIVITY; DRUG SYNTHESIS; ENANTIOMER; ENZYME INHIBITION; INTRAPERITONEAL DRUG ADMINISTRATION; NONHUMAN; PRIORITY JOURNAL; RAT; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION; ANIMAL; COMPARATIVE STUDY; DRUG ANTAGONISM; ENZYMOLOGY; KINETICS; METABOLISM;

ANIMALS; BRAIN; INDANS; ISOENZYMES; KINETICS; MONOAMINE OXIDASE; MONOAMINE OXIDASE INHIBITORS; RATS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0031596711     PISSN: 03036995     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-7091-6499-0_30     Document Type: Article

References (16)

1. Birkmayer W, Riederer P, Youdim MBH, Linauer W (1975) Potentiation of antiakinetic effect after L-dopa treatment by an inhibitor of MAO-B, 1-deprenyl. J Neural Transm 36: 303-323
2. Engberg G, Elebring T, Nissbrandt H (1991) Deprenyl (selegiline), a selective MAO-B inhibitor with active metabolites. J Pharmacol Exp Ther 259: 841-847
3. Finberg JPM, Tenne M, Youdim MBH (1981) Tyramine antagonistic properties of AGN-1135, an irreversible inhibitor of monoamine oxidase type B. Br J Pharmacol 73: 65-74
4. Ghislandi V, Vercesi D (1976) Scissione ottica E configurazione dell'1-aminobenzociclobutaene e dell'1-aminoindano. Boll Chim Farm 115: 489-500
5. Hazelhoff B, De Vries J, Dijkstra D, de Jong W, Horn A (1985) The neuropharmacological profile of N-Methyl-N-propargyl-2-aminotetralin. Naunyn Schmiedebergs Arch Pharmacol 330: 50-59
6. Kalir A, Sabbagh A, Youdim MBH (1981) Selective acetylenic "suicide" and reversible inhibitors of monoamine oxidase types A and B. Br J Pharmacol 73: 55-64
7. Martin Y, Martin W, Taylor J (1975) Regression analysis of the relationship between physical properties and the in vitro inhibition of monoamine oxidase by propynylamines. J Med Chem 18: 883-888
8. O'Carrol AM, Fowler CJ, Philips JP, Tobbia I, Tipton KF (1983) The deamination of dopamine by human brain monoamine oxidase. Specificity for the two enzyme forms in seven brain regions. Naunyn Schmiedebergs Arch Pharmacol 332: 198-202
9. Otsaka S, Kobayashi Y (1964) A radioisotopic assay for monoamine oxidase determinations in human plasma. Biochem Pharmacol 13: 995-1006
10. Parkinson Study Group. DATATOP (1989) A multicenter controlled clinical trial in early Parkinson's disease. Arch Neurol 46: 1052-1060
11. Parkinson Study Group. DATATOP (1993) Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 328: 176-183
12. Polymeropoulos E (1993) 1-Deprenyl: a unique MAO-B inhibitor. In: Szelenyi I (ed) Inhibitors of monoamine oxidase. Birkhäuser, Basel, pp 109-124
13. Sterling J, Levy R, Veinberg A, Goldenberg W, Finberg J, Youdim MBH, Gutman A (1996) Monofluorinated derivatives of N-propargyl-1-aminoindan and their use as inhibitors of monoamine oxidase. USP 4,486,541
14. Youdim MBH (1995) The advent of selective monoamine oxidase A inhibitor antidepressants devoid of the cheese reaction. Acta Psychiatr Scand 91 [Suppl 386]: 5-7
15. Youdim MBH, Finberg J, Levy R, Sterling J, Lerner D, Berger-Peskin T, Yellin H (1995) R-Enantiomers of N-propargyl-aminoindan compounds, their preparation and pharmaceutical compositions containing them. USP 5,457,133
16. Yu P, David B, Boulton A (1992) Aliphatic propargylamines: potent, selective, irreversible monoamine oxidase B inhibitors. J Med Chem 35: 3705-3713